Phase II Trial of Oral Rubitecan in Previously Treated Pancreatic Cancer Patients

Learning Objectives After completing this course, the reader will be able to: Describe the current standard of care for the treatment of advanced pancreatic cancer. State the rationale for treating refractory, advanced pancreatic cancer with the novel oral topoisomerase‐I inhibitor rubitecan. Descri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2005-03, Vol.10 (3), p.183-190
Hauptverfasser:	Burris, Howard A., Rivkin, Saul, Reynolds, Robert, Harris, Jules, Wax, Arnold, Gerstein, Hal, Mettinger, Karl L., Staddon, Arthur
Format:	Artikel
Sprache:	eng
Schlagworte:	9‐nitrocamptothecin Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - therapeutic use Disease Progression Female Humans Male Middle Aged Pancreatic neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Rubitecan Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!